Huntsman Corporation Q1 Loss Widens

Huntsman reported a first-quarter net loss of $53 million, widening sharply from a $5 million loss a year earlier, with EPS at a loss of $0.31 versus a $0.03 loss last year. Revenue was essentially flat at $1.42 billion, up slightly from $1.41 billion, indicating stable top-line performance despite weaker profitability. The stock was up 4.38% in after-hours trading to $15.00, suggesting a mixed market reaction.

Analysis

The market is likely reading this as a cost-structure problem rather than a demand problem: flat top-line with widening losses usually means the pain is in mix, fixed-cost absorption, or pricing discipline, not volume collapse. That matters because if industrial demand were the real issue, you’d expect a faster, broader multiple reset across the chemical group; instead, the after-hours bounce suggests investors are still willing to underwrite a second-half margin repair story. The key second-order risk is that stable revenue at a lower margin base leaves less cushion if end-market restocking stalls again.

For competitors, the near-term beneficiary is anyone with cleaner feedstock exposure, more flexible production, or better specialty mix — those peers can take share if Huntsman has to defend volume with price. The loser is likely downstream buyers that had been relying on price stability; if Huntsman is protecting utilization, that can quietly pressure industry pricing and make the eventual recovery more asymmetric for higher-cost producers. In chemicals, one quarter of weak earnings can bleed into channel behavior for 1-2 quarters as customers delay orders waiting for discounting.

The contrarian view is that the loss widening may be less important than the market thinks if the business is near trough earnings and the delta is mostly non-cash or temporary. In that case, the stock’s move higher is a signal that positioning was already bearish and the bar for disappointment was low. But if margin compression persists for another quarter, the market will stop treating this as a cyclical trough and start pricing in a longer de-rating window of 3-6 months.

Key Decisions for Investors

• Avoid chasing the after-hours bounce in HUN; use any strength into the next 1-2 sessions to trim or short against resistance, targeting a 10-15% downside if the market refocuses on margin deterioration.
• Pair trade: long higher-quality specialty chemicals or diversified industrial chemical exposure vs short HUN for the next 1-2 quarters; the trade favors companies with stronger pricing power and better fixed-cost leverage if the sector stays soft.
• If already short HUN, keep the position but add only on a failed rally above the post-earnings high; the near-term upside is likely capped, while the downside improves if management guidance does not show margin recovery within the next quarter.
• For event-driven accounts, consider a limited-risk put spread on HUN expiring after the next earnings cycle; this captures the risk that the market quickly concludes the issue is structural rather than transitory.
• Set a catalyst watch on the next quarter’s gross margin and volume commentary; if management signals another quarter of flat revenue with worse profitability, the thesis shifts from cyclical volatility to earnings revision risk over 3-6 months.